Agape ATP Corp (ATPC) FinancialsATPCAgape ATP Corp

Agape ATP Corp (ATPC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Others – Products for the provision of complementary health therapies, accounting for 78.1% of total sales, equivalent to $213.74K. Other significant revenue streams include Health and wellness services and Ionized Cal-Mag. Understanding this composition is critical for investors evaluating how ATPC navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Agape ATP Corp maintains a gross margin of 85.96%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4023.77%, while the net margin is 610.47%. These profitability ratios, combined with a Return on Equity (ROE) of -5.36%, provide a clear picture of how effectively ATPC converts its operational activities into shareholder value.

In the context of the broader market, ATPC competes directly with industry leaders such as SCNI and PAVS. With a market capitalization of $1.25M, it holds a significant position in the sector. When comparing efficiency, ATPC's gross margin of 85.96% stands against SCNI's -272.17% and PAVS's 19.98%. Such benchmarking helps identify whether Agape ATP Corp is trading at a premium or discount relative to its financial performance.

Agape ATP Corp has shown a concerning financial performance with a net income of -327619 USD in Q1 2026 and a gross margin that, despite being high at 85.96% in Q2 2026, does not translate into profitability. The company has consistently reported negative net income, with a net margin of 610.47% in Q2 2026, but this is due to a low revenue base rather than strong operational performance.